Adia Med of Winter Park LLC Chronic Kidney Disease Research Study
2026年6月16日 更新者:Adia Med of Winter Park LLC
The goal of this clinical trial is to learn whether a new regenerative treatment called AdiaVita, made from umbilical cord blood-derived stem cells and exosomes combined with glutathione, is safe and can help improve kidney function in adults with chronic kidney disease (CKD).
In this condition, the kidneys gradually lose their ability to filter blood as well as they should.
The main questions it aims to answer are whether AdiaVita plus glutathione improves kidney function better than control treatments, as measured by blood tests for estimated glomerular filtration rate (eGFR) and creatinine levels, and whether the treatment is safe with acceptable side effects.
Researchers will compare three groups.
One group will receive AdiaVita plus glutathione.
A second group will receive glutathione plus a placebo for AdiaVita.
The third group will receive placebos for both treatments.
A placebo looks like the real treatment but contains no active ingredients.
This will help determine if the full treatment works better than the controls.
Approximately 100 adults aged 18 to 80 with stage 2 to 4 chronic kidney disease may participate.
Participants will be randomly assigned to one of the three treatment groups.
They will receive monthly intravenous infusions at the clinic for the first three months and apply a skin spray twice daily at home during that period.
The study lasts 12 months total for each participant, with regular visits for blood tests, physical exams, and safety monitoring.
Certain participants in the control groups may switch to the active AdiaVita treatment after three months if they meet safety criteria.
This is a single-blind study, meaning participants will not know which treatment they receive.
Participant safety is closely monitored by the research team and an independent board throughout the study.
研究概览
地位
招聘中
详细说明
This study evaluates the safety and preliminary efficacy of a regenerative therapy combined with glutathione in adults with chronic kidney disease.
The primary objective is to determine whether the treatment improves kidney function as measured by estimated glomerular filtration rate and serum creatinine levels.
Secondary objectives focus on assessing safety, tolerability, and the incidence of adverse events.
The study is designed as a randomized, single-blind, controlled trial with three treatment arms.
Participants include approximately 100 adults aged 18 to 80 diagnosed with stage 2-4 chronic kidney disease.
Subjects are recruited through clinical sites, outreach efforts, and partnerships with healthcare providers.
Participants are randomly assigned to receive either the investigational therapy with glutathione, an active control, or a full placebo.
The intervention consists of monthly intravenous infusions over a three-month initial treatment period.
At-home administration of a topical spray is also required during the treatment phase.
A crossover option allows certain participants to receive the investigational therapy after the initial phase if safety criteria are met.
The total study duration per participant is 12 months, including treatment and follow-up.
Data collection includes laboratory assessments, physical exams, and monitoring of adverse events.
Safety oversight is provided through structured monitoring procedures and an independent review board.
Risks include infusion-related reactions, allergic responses, and unknown long-term effects.
Potential benefits include improved kidney function and contributions to scientific knowledge.
All data are securely stored and analyzed, with confidentiality maintained and results reported in a de identified manner.
No monetary incentives are offered, and Patient instead pay a fixed fee of $15,000 for Phase One, which covers all procedures and includes crossover if applicable.
Outcomes will contribute to scientific knowledge regarding the safety and possible clinical utility of stem cell-based therapies for CKD.
研究类型
介入性
注册 (估计的)
100
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Larry Powalisz
- 电话号码:3217880850
- 邮箱:research@adiamed.com
学习地点
-
-
Florida
-
Winter Park、Florida、美国、32789
- 招聘中
- Adia Med Of Winter Park
-
接触:
- Larry Powalisz
- 电话号码:3217880850
- 邮箱:research@adiamed.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Age 18-80 years
- Confirmed CKD diagnosis (eGFR 15-89 mL/min/1.73 m²)
- Willingness to consider experimental treatments and comply with study requirements
- Ability to obtain required bloodwork
- Ability to attend all scheduled visits
- Able to meet study cost requirements ($15,000 study fee) as described in the informed consent
Exclusion Criteria:
- Has
- Severe allergies to study products
- Significant uncontrolled medical conditions
- Immunocompromised
- Malignancy history
- Unstable medication regimen or inconsistent medication adherence (e.g., frequent medication changes or missed doses) within 30 days prior to Baseline, at Investigator discretion
- Current dialysis (hemodialysis or peritoneal dialysis) or planned initiation of dialysis during the study period
- Pregnancy or breastfeeding (if applicable)
- Participation in another interventional trial within 30 days
- Has had Kidney transplant
- Prior stem cell or glutathione therapy: History of stem cell therapy (including umbilical cord blood-derived stem cells or exosomes) or glutathione therapy (intravenous or topical) at any time prior to screening
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Stem Cell + Glutathione
|
静脉输注含有活单核细胞(包括造血和间充质干/基质细胞)及外泌体的冷冻保存异体脐带血来源产品。
Reduced L-glutathione administered Intravenous infusion once monthly for 3 months (Initial Treatment Schedule)
Transdermal glutathione spray (4 sprays applied twice daily to the skin).
|
|
有源比较器:Glutathione Control (with Crossover)
|
Reduced L-glutathione administered Intravenous infusion once monthly for 3 months (Initial Treatment Schedule)
Matched placebo intravenous infusion (administered in the same volume and manner as stem cell and exosome product).
Matched placebo transdermal spray (4 sprays applied twice daily).
|
|
安慰剂比较:Placebo Control (with Crossover)
|
Matched placebo intravenous infusion (administered in the same volume and manner as stem cell and exosome product).
Matched placebo transdermal spray (4 sprays applied twice daily).
Matched placebo intravenous infusion administered on the same schedule as active glutathione IV.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
大体时间:Baseline to Month 6
|
Change from baseline in eGFR (mL/min/1.73
m²)
|
Baseline to Month 6
|
|
Change from Baseline in Serum Creatinine
大体时间:Baseline to Month 6
|
Change from baseline in serum creatinine level (mg/dL)
|
Baseline to Month 6
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants with Treatment-Emergent Adverse Events and Serious Adverse Events
大体时间:From first infusion through Month 12
|
Number and severity of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) in each treatment arm
|
From first infusion through Month 12
|
|
Change from Crossover Baseline in Estimated Glomerular Filtration Rate (eGFR)
大体时间:Month 3 to Month 9 (crossover participants only)
|
Change in eGFR from the start of crossover (Month 3) to Month 9 in participants from Arms 2 and 3 who receive AdiaVita
|
Month 3 to Month 9 (crossover participants only)
|
|
Change from Crossover Baseline in Serum Creatinine
大体时间:Month 3 to Month 9 (crossover participants only)
|
Change in serum creatinine from the start of crossover (Month 3) to Month 9 in participants from Arms 2 and 3 who receive AdiaVita
|
Month 3 to Month 9 (crossover participants only)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Richard Edwards, DO、Adia Med of Winter Park LLC
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年5月18日
初级完成 (估计的)
2028年1月1日
研究完成 (估计的)
2029年1月1日
研究注册日期
首次提交
2026年5月1日
首先提交符合 QC 标准的
2026年5月1日
首次发布 (实际的)
2026年5月7日
研究记录更新
最后更新发布 (实际的)
2026年6月17日
上次提交的符合 QC 标准的更新
2026年6月16日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- Adia Med CKD Research Study
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
IPD 计划说明
No, we do not plan on sharing IPD data with other researchers.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.